

Study Number: I94043

Test Type: TOX

Route: Dosing in Water

Species/Strain: Mouse/B6C3F1/N

Study Number:

Study Gender:

PWG Approval Date

PA03: Non-Neoplastic Lesion Summary with Percent Incidence

Test Compound: Sodium Metavanadate

CAS Number: 13718-26-8

I94043

Female

See web page for date of PWG Approval

Date Report Requested: 09/02/2020

Time Report Requested: 10:29:12

Lab: Burleson Research Technologies

Study Number: I94043
Test Type: TOX
Route: Dosing in Water
Species/Strain: Mouse/B6C3F1/N

PA03: Non-Neoplastic Lesion Summary with Percent Incidence
Test Compound: Sodium Metavanadate
CAS Number: 13718-26-8

Date Report Requested: 09/02/2020
Time Report Requested: 10:29:12
Lab: Burleson Research Technologies

Female: Immunopath

	Treatment Groups (ppm)					
	0	31.3	62.5	125	250	500
Disposition Summary						
Animals Initially In Study	8	8	8	8	8	8
Early Deaths						
Survivors						
Scheduled sacrifice, terminal (SD 28)	8	8	8	8	8	8
Animals Examined Microscopically	8	8	8	8	8	8
ALIMENTARY SYSTEM						
LIVER	(8)	(8)	(8)	(8)	(8)	(8)
INFLAMMATION; FOCAL	8 (100%)	8 (100%)	8 (100%)	8 (100%)	8 (100%)	8 (100%)
CARDIOVASCULAR SYSTEM						
No Tissues/Organs Examined						
ENDOCRINE SYSTEM						
ADRENAL GLAND, RIGHT	(8)	(8)	(8)	(8)	(8)	(8)
HYPERPLASIA; SUBCAPSULAR	4 (50%)	6 (75%)	8 (100%)	6 (75%)	6 (75%)	8 (100%)
GENERAL BODY SYSTEM						
No Tissues/Organs Examined						
GENITAL SYSTEM						
COAGULATING GLAND	(1)	(0)	(0)	(0)	(0)	(0)

Study Number: I94043

Test Type: TOX

Route: Dosing in Water

Species/Strain: Mouse/B6C3F1/N

PA03: Non-Neoplastic Lesion Summary with Percent Incidence

Test Compound: Sodium Metavanadate

CAS Number: 13718-26-8

Date Report Requested: 09/02/2020

Time Report Requested: 10:29:12

Lab: Burlinson Research Technologies

Female: Immunopath

	Treatment Groups (ppm)					
	0	31.3	62.5	125	250	500
HEMATOLYMPHOID SYSTEM						
BALT	(8)	(8)	(8)	(8)	(8)	(8)
BONE MARROW	(8)	(8)	(8)	(8)	(8)	(8)
LYMPH NODE, MESENTERIC	(8)	(8)	(8)	(8)	(8)	(8)
LYMPH NODE, POPLITEAL	(8)	(8)	(8)	(8)	(8)	(8)
SPLEEN	(8)	(8)	(8)	(8)	(8)	(8)
RED PULP; EXTRAMEDULLARY HEMATOPOEISIS; INCREASED	1 (13%)					
THYMUS	(8)	(8)	(8)	(8)	(8)	(8)
CYST		2 (25%)	2 (25%)	4 (50%)	1 (13%)	
INTEGUMENTARY SYSTEM						
No Tissues/Organs Examined						
MUSCULOSKELETAL SYSTEM						
No Tissues/Organs Examined						
NERVOUS SYSTEM						
No Tissues/Organs Examined						
RESPIRATORY SYSTEM						
LUNG	(8)	(8)	(8)	(8)	(8)	(8)
CONGESTION			1 (13%)			
INTERSTITIUM; INFILTRATE, CELLULAR; MIXED	1 (13%)		1 (13%)	1 (13%)	1 (13%)	
INFILTRATE, CELLULAR; HISTIOCYTE			1 (13%)			
SPECIAL SENSES SYSTEM						
No Tissues/Organs Examined						
URINARY SYSTEM						
KIDNEY	(1)	(0)	(0)	(0)	(0)	(0)
KIDNEY, RIGHT	(8)	(8)	(8)	(8)	(8)	(8)
INTERSTITIUM; INFILTRATE, CELLULAR; MIXED				2 (25%)		
PELVIS; INFILTRATE, CELLULAR; MIXED	4 (50%)	7 (88%)	7 (88%)	7 (88%)	3 (38%)	4 (50%)

Study Number: I94043

Test Type: TOX

Route: Dosing in Water

Species/Strain: Mouse/B6C3F1/N

PA03: Non-Neoplastic Lesion Summary with Percent Incidence

Test Compound: Sodium Metavanadate

CAS Number: 13718-26-8

Date Report Requested: 09/02/2020

Time Report Requested: 10:29:12

Lab: Burleson Research Technologies

LEGEND

Number of animals examined given for each tissue. If none of the animals examined have the specific lesion then there is a blank for that dose group for that specific lesion.

Number of animals with observation reported with percent incidence in parentheses

Phase day range of terminal sacrifice shown in parentheses in disposition summary

SD – Study Day

**** END OF REPORT ****